Stockscreener 앱 받기
0.3626
8.80%
-0.0351
전일 마감가:
$0.3977
열려 있는:
$0.3878
하루 거래량:
1.36M
Relative Volume:
0.41
시가총액:
$47.83M
수익:
$36.86M
순이익/손실:
$-171.67M
주가수익비율:
-0.2417
EPS:
-1.5
순현금흐름:
$-171.05M
1주 성능:
-5.50%
1개월 성능:
+19.74%
6개월 성능:
-81.96%
1년 성능:
-89.52%
1일 변동 폭
$0.36
$0.3941
1주일 범위
$0.3447
$0.4423
52주 변동 폭
$0.2589
$3.63
Mersana Therapeutics Inc Stock (MRSN) Company Profile
명칭
Mersana Therapeutics Inc
전화
617-498-0020
주소
840 MEMORIAL DRIVE, CAMBRIDGE
MRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.3627 | 47.83M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.78 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.31 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.38 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.80 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.47 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | William Blair | Outperform |
| 2024-11-15 | 재개 | Citigroup | Buy |
| 2024-03-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-27 | 다운그레이드 | Truist | Buy → Hold |
| 2023-07-27 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-06-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 개시 | Guggenheim | Buy |
| 2023-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 개시 | Citigroup | Buy |
| 2022-11-21 | 개시 | Truist | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-08-30 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-04-29 | 개시 | BTIG Research | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-11-14 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
Mersana Therapeutics Inc [MRSN] stock for 2,061 USD was sold by Mandelia Ashish - knoxdaily.com
Renaissance Technologies LLC Has $867,000 Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics Inc (MRSN) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Mersana Therapeutics (MRSN) Expected to Announce Earnings on Thursday - Defense World
XTX Topco Ltd Sells 283,725 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
MRSN (Mersana Therapeutics Inc) may reap gains as insiders became active recently - knoxdaily.com
Holdings of Mersana Therapeutics Inc (MRSN) are aligned with the stars - Sete News
Investors’ Faith in Mersana Therapeutics Inc (MRSN) could reap rewards if they hold on for the long haul - uspostnews.com
Investor’s Delight: Mersana Therapeutics Inc (MRSN) Closes Strong at 0.36, Up 0.44 - DWinneX
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Stock Holdings Lifted by Geode Capital Management LLC - Defense World
MRSN Shares Experience Decline in Value - knoxdaily.com
Mersana therapeutics VP Mandelia sells $1,128 in stock - MSN
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting | MRSN Stock News - GuruFocus
Mersana Therapeutics Announces Presentations on Emiltatug Ledadotin at ASCO 2025 Annual Meeting - Nasdaq
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting - GlobeNewswire
Breakthrough Cancer Drug Emi-Le Earns Dual FDA Fast Track Status: Key Data Coming at ASCO 2025 - Stock Titan
Daily Market Movement: Mersana Therapeutics Inc (MRSN) Sees a 15.02 Increase, Closing at 0.38 - DWinneX
Mersana Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
It makes sense and dollars to buy Mersana Therapeutics Inc (MRSN) stock - Sete News
Mersana Therapeutics Inc [MRSN] Insider Activity: An Update for Investors - knoxdaily.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Wellington Management Group LLP - Defense World
Sei Investments Co. Purchases Shares of 69,527 Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall - BioWorld MedTech
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MRSN stock touches 52-week low at $0.3 amid sharp annual decline - Investing.com
Mersana Strengthens Team with Strategic 26,790-Share RSU Grant to New Hire - Stock Titan
MRSN stock touches 52-week low at $0.3 amid sharp annual decline By Investing.com - Investing.com South Africa
When Would Be The Best Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - stocksregister.com
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress - The Manila Times
Mersana Therapeutics Announces Upcoming Oral Presentation - GlobeNewswire
FDA Fast-Tracked Breast Cancer Drug Shows Promise: Key Clinical Data Coming at ESMO 2025 - Stock Titan
Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World
MRSN stock plunges to 52-week low of $0.37 amid market challenges - Investing.com India
MRSN stock plunges to 52-week low of $0.37 amid market challenges By Investing.com - Investing.com South Africa
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - simplywall.st
Drug developers show mixed performance in early 2025 - BioWorld MedTech
MRSN stock touches 52-week low at $0.43 amid sharp decline - Investing.com India
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MRSN stock plunges to 52-week low of $0.45 amid market challenges - Investing.com Australia
Mersana at Leerink Global Healthcare Conference: Strategic ADC Insights By Investing.com - Investing.com Canada
MRSN stock plunges to 52-week low of $0.45 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimates for Mersana Therapeutics Lowered by Wedbush - MarketBeat
Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Simply Wall St
Mersana Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Q1 EPS Estimate for Mersana Therapeutics Reduced by Analyst - Defense World
Brokers Issue Forecasts for MRSN Q1 Earnings - Defense World
Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Yahoo Finance
Mersana Therapeutics Inc (MRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):